Calgary, Alberta, Canada, October 3, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is announcing that, further to the Company’s press releases of May 16, 2024,...
